相关实验视频
Updated: Jul 9, 2025

Pentylenetetrazole-Induced Kindling Mouse Model
Published on: June 12, 2018
揭露隐藏的风险:PDE5抑制剂与发作易感性之间的令人惊的联系
Alex Luiz Menezes da Silva1, Chirlene Pinheiro Nascimento1, Julianne Elba Cunha Azevedo1
1Laboratory of Pharmacology and Toxicology of Natural Products, Institute of Biological Sciences, Federal University of Pará, UFPA, Belém, Pará, Brazil.
固酶5抑制剂 (PDE5i) 改变电皮质图 (ECoG) 的记录,增加了发作的易感性. 费诺巴比塔尔和泽有效控制了大鼠中PDE5i和PTZ诱导的发作.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物医学工程 生物医学工程
背景情况:
- 固酶5抑制剂 (PDE5i) 是对勃起功能障碍的主要治疗方法.
- 包括发作在内的中枢神经系统影响与PDE5i使用有关.
- 这项研究研究了PDE5i对大脑活动和发作值的影响.
研究的目的:
- 在老鼠中分析西尔德纳菲尔和塔达拉菲尔诱导的电皮质图 (ECoG) 变化.
- 评估PDE5i对发作值的影响,使用型模型.
- 评估抗发作药物在治疗PDE5i相关发作的有效性.
主要方法:
- 在三个实验中使用了108只Wistar老鼠.
- 电脑心电图记录分析了对PDE5i (西尔德纳菲尔,塔达拉菲尔),PDE5i + Pentylenetetrazole (PTZ) 和抗治疗的反应.
- 统计学意义在p<0.05.05时确定.
主要成果:
- 西尔德纳菲尔和塔达拉菲尔的使用增加了ECoG记录中的α和β振荡功率.
- 与PTZ相结合的PDE5i显著增强了发作活动,而西尔德纳菲尔显示出比塔达拉菲尔更大的功效.
- 费诺巴比塔尔和迪亚泽巴姆在PDE5i + PTZ组合引起的发作上表现出更好的控制.
结论:
- PDE5i显著改变运动皮层ECoG,导致大脑异步.
- PDE5i增强了PTZ的前性作用,降低了的值.
- 抗发作药物,如费诺巴比塔尔和迪亚泽帕姆在控制PDE5i诱导的活动方面是有效的.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...

